Ascendis Pharma A/S (ASND)
Summary
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia.
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 20,095 | $2.87M | $5.35M | $2.48M | 86.38% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 27 | $6,175.71 | $7,163.1 | $987.39 | 15.99% |
| YA Yinka Akinsola Blue Trust Inc. | 170 | $23,403.9 | $45,128.2 | $21,724.3 | 92.82% |
 Joseph Castro Nuveen LLC | 6,051 | $1.04M | $1.61M | $562,917.62 | 53.9% |
| MPM Mark P. Mennitt CenterBook Partners LP | 6,013 | $1.38M | $1.6M | $221,098.01 | 16.08% |
Ascendis Pharma A/S (ASND) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ascendis Pharma A/S ever had a stock split?
Ascendis Pharma A/S Profile
| Biotechnology Industry | Healthcare Sector | Jan Moller Mikkelsen CEO | NASDAQ (NGS) Exchange | K08588103 CUSIP |
| DK Country | 1,017 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Ascendis Pharma A/S is an innovative biopharmaceutical company that dedicates its efforts to addressing unmet medical needs through the development of groundbreaking therapies. Founded in 2006 and headquartered in Hellerup, Denmark, the company has established itself as a leader in the field of biopharmaceuticals, particularly focusing on rare diseases within endocrinology and oncology. Ascendis Pharma leverages its proprietary technology and deep scientific expertise to create therapies that aim to significantly improve patients' lives across the globe.
Products and Services
- SKYTROFA
Ascendis Pharma's SKYTROFA is a pivotal drug designed for the treatment of growth hormone deficiency (GHD) in patients. This therapeutic solution represents the company's commitment to addressing the challenges faced by individuals dealing with GHD, offering them a potentially transformative treatment option.
- Endocrinology Rare Disease Product Candidates
The company is developing a rich pipeline of three independent rare disease product candidates within the endocrinology domain. These are currently in clinical development stages, showcasing Ascendis Pharma's focused endeavor to bring novel treatments to patients suffering from rare endocrine disorders.
- Oncology Therapeutic Candidates
In addition to its work in endocrinology, Ascendis Pharma is actively advancing therapeutic candidates in the field of oncology. This effort demonstrates the company's dedication to extending its impact beyond endocrinology and into other areas where there are substantial unmet medical needs, particularly in the treatment of various cancers.
